跳轉至內容
Merck
  • Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.

Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.

Parkinsonism & related disorders (2014-10-13)
Fabrizio Stocchi, Ann Hsu, Sarita Khanna, Aaron Ellenbogen, Andreas Mahler, Grace Liang, Ulrich Dillmann, Robert Rubens, Sherron Kell, Suneel Gupta
摘要

IPX066, an investigational extended-release carbidopa-levodopa (CD-LD) preparation, has demonstrated a rapid attainment and prolonged maintenance of therapeutic LD plasma concentrations in advanced Parkinson's disease (PD). This phase-3 crossover study assessed its efficacy and safety vs. CD-LD plus entacapone (CL + E). At baseline, all patients had motor fluctuations despite a stable regimen of CL + E or CD-LD-entacapone combination tablets (CLE). The study included a 6-week conversion from CL + E or CLE to IPX066, followed by two 2-week, double-blind crossover treatment periods in randomized order, one on IPX066 (and placebo CL + E), the other on CL + E (and placebo IPX066), separated by 1-week open-label IPX066 treatment. The primary efficacy measure was mean percent daily "off" time during waking hours (from patient diaries). Of 91 randomized patients, 84 completed the study. Their median daily LD dosage was 1495 mg from IPX066 and 600 mg from CL + E, corresponding, after correction for bioavailability, to an approximately 22% higher LD exposure on IPX066. Compared with CL + E, IPX066 demonstrated a lower percent "off" time (24.0% vs. 32.5%; p < 0.0001), lower "off" time (3.8 vs. 5.2 h/day; p < 0.0001), and higher "on" time without troublesome dyskinesia (11.4 vs. 10.0 h/day; p < 0.0001). Other endpoints, including patient-reported treatment preference, also favored IPX066 (p < 0.05). During double-blind treatment, 20.2% and 13.6% of patients reported adverse events on IPX066 and CL + E, respectively. The most common were dyskinesia (4 patients), insomnia (3), and confusional state (3) for IPX066, and fall (2) for CL + E. In advanced PD, IPX066 showed improved efficacy, compared with CL + E, and appeared to be well tolerated.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
恩他卡朋, ≥98% (HPLC)
恩他卡朋, European Pharmacopoeia (EP) Reference Standard